60 Degrees Pharmaceuticals (SCTP) investor relations material

Strategic focus and product overview

• Focused on developing and commercializing small molecule therapeutics for vector-borne diseases, with Aracoda approved for malaria prevention since 2018.

• Management team responsible for FDA approval remains in place, aiming to expand Aracoda's label to new indications.

• Sales of Aracoda began in 2019 but were initially hampered by the pandemic; sales later increased, driven by unexpected demand for chronic babesiosis.

• Gross margin stabilized at about 50% as volume increased, with profitability expected at scale.

• Patent life for Aracoda extends to February 2035, with potential to reach over $200 million in sales.

Market research and commercial strategy

• Market research revealed that up to 70% of sales were for chronic babesiosis, a previously undescribed disease.

• Malaria prevention market faces challenges due to lack of vaccines and complex medication regimens, with Aracoda offering a simpler alternative.

• Brand recognition is low, but healthcare providers and patients value Aracoda's features; some are willing to pay a premium.

• Commercial pilot program includes electronic outreach, inside sales reps, and a co-pay assistance program, with data expected by year-end to inform 2026 scaling decisions.

Babesiosis program and clinical development

• Babesiosis shares similarities with malaria and can be transmitted by ticks and blood donation; new FDA-approved diagnostics have improved detection.

• Persistent low-level infection is common, especially in immunosuppressed patients, and may contribute to chronic symptoms.

• Tefaniquin, Aracoda's active ingredient, has shown efficacy in animal studies and a Yale case series for relapsing babesiosis.

• Three targeted clinical trials are underway: a randomized trial in severe cases, an open-label study in high-risk patients, and a chronic babesiosis trial starting in Q4.

• The chronic babesiosis trial aims to enroll 100 patients, using broad diagnostic criteria and focusing on fatigue outcomes and diagnostic confirmation.